Prime Medicine Stock Soars 11.9% on Strategic Restructuring

Prime Medicine's stock surged 11.9% in pre-market trading on July 7, 2025, reflecting significant investor interest and optimism in the company's recent developments and strategic shifts.

Prime Medicine has recently announced a strategic restructuring, focusing its internal efforts on in vivo programs for large genetic liver diseases, specifically Wilson’s Disease and Alpha-1 Antitrypsin Deficiency/AATD. The company will also continue its in vivo Cystic Fibrosis program with external support, as well as partnered programs for Prime Edited CAR-T products. This shift comes after the announcement of initial positive data from the Phase 1/2 clinical trial of PM359 in Chronic Granulomatous Disease/CGD, which provided clinical proof-of-concept for Prime Editing as a transformative gene editing technology.

Despite the positive developments, Prime Medicine is exploring options for the continued clinical development of PM359 external to the company and ceasing further internal efforts in X-linked CGD. The company expects to file an Investigational New Drug/IND application and/or Clinical Trial Application/CTA for its Wilson’s Disease program in H1 2026, and for its AATD program in mid-2026. Initial clinical data from both programs are anticipated in 2027.